Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 主要终点
- the prevalance of non-alcoholic fatty liver in inflammatory bowel disease participants
研究概览
简要总结
To assess the prevalance of non_alcoholic fatty liver diseases in inflammatory bowel disease patients and its relation to type of treatment given and disease severity
详细描述
Inflammatory bowel diseases (IBD) including Crohns disease (CD) and ulcerative colitis (UC) are chronic relapsing disorders that often require long-term therapy and follow up .
They are recognized for their complex pathophysiology that involves innate immune system deregulation and altered microbiome in genetically predisposed individuals. Non-alcoholic fatty liver disease (NAFLD) includes a wide spectrum of disorders, ranging from hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). NAFLD patients are at high risk for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Also NAFLD is typically associated with altered metabolism and metabolic syndrome (MetS).
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Crohn's disease (CD) patients
- •ulcerative colitis (UC) patients
排除标准
- •diabetic patients
- •BMI equal and more than 30.0-34.9(class I obesity)
结局指标
主要结局
the prevalance of non-alcoholic fatty liver in inflammatory bowel disease participants
时间窗: one year
u/s will be done to all participants of inflammatory bowel disease to asses the rate of non-alcoholic fatty liver affection of all patients
次要结局
- the Correlation between immunosuppressive drugs and prevalance of non-alcoholic fatty liver affection in inflammatory bowel disease participants(one year)
研究者
Al shymaa aAdel hakm Ahmed Ali
Principal Investigator
Assiut University